Medway school of pharmacy

I obtained my BSc (Hons) in Microbiology and Genetics from University College London (UCL) in 1990 and my MSc (1992), PhD (1999) and DLSHTM (2000) from the London School of Hygiene & Tropical Medicine (LSHTM). Prior to my appointment as a Senior Lecturer in Biological Sciences at the Medway School of Pharmacy I was a Principal Investigator at the MRC/UCL Centre for Medical Molecular Virology, Windeyer Institute, University College London. This post was funded by the MRC and industry. My research is focused primarily on antibody responses to SARS coronavirus, pandemic/inter-pandemic influenza and other emerging viruses. I have developed an independent research portfolio on the use of retroviral pseudotypes as surrogates for the serological study of emerging viruses and have been invited to give many lectures/seminars/workshops at conferences, to public health institutes (human and veterinary) and to biotech and pharmaceutical companies. In previous posts, I have undertaken research on the development of DNA vaccines for cytomegalovirus (Post-Doctoral research at the Royal Free Hospital), and the role of superoxide dismutase in the response of Trypanosoma cruzi to trypanocidal agents (PhD research at LSHTM). I am a Member of the International Society for Influenza and other Respiratory Virus Diseases (ISIRV), the Biochemical Society and the Society for General Microbiology (SGM).

My research interests lie primarily in emerging and transboundary viruses and the methods for their control. I have established novel virus neutralization assays for high-containment viruses (Influenza H5N1/H7N1, SARS coronavirus and rabies) using retroviral and lentiviral vector technologies. In January 2011 I have established (in collaboration with Dr Simon Scott) the Viral Pseudotype Unit (VPU) within the School of Pharmacy, a purpose built dedicated pseudotype assay laboratory. The role of the VPU will be to act as an interface between academia, industry, animal and public health laboratories with the purpose of translating basic virus research into assays that can be readily employed for the efficacy testing of vaccines, antivirals and therapeutic antibodies. I maintain many active and productive collaborations (in the UK and worldwide) with public health laboratories (Health Protection Agency/WHO/Veterinary Laboratories Agency/OIE), vaccine clinical trial centers (University of Siena and CEVAC, Ghent) and industry (vaccine and biotech companies). Further information on my research activities and networks can be found on my LinkedIn Profile. Current projects in the laboratory include:

• The development of surface-engineered retroviral vectors to study the antigenic evolution of influenza H5 and H7 viruses in birds and humans.
• The development of novel serologic and pharmacologic assays for influenza neuraminidase (NA). These can be used to study (a) the protective role of NA antibodies elicited by vaccination and during natural infection, (b) the antigenic drift of neuraminidase and (c) the mechanism of resistance to antiviral drugs that target NA.
• Comparative serology for influenza viruses in order to establish more accurate correlates of immunity.
• The pre-clinical evaluation of monoclonal antibodies as novel therapeutics for influenza.
• The serological response to LPAI and HPAI influenza viruses in birds.
• The development of multiplex neutralization assays for emerging viruses using luminescence and fluorescence platforms.
• The translation of "sequence-file serology" to public health and industrial laboratories worldwide.

back to top

• Davide Corti, Jarrod Voss, Steven J. Gamblin, Giosiana Codoni, Annalisa Macagno, David Jarrossay, Sebastien G. Vachieri, Debora Pinna, Andrea Minola, Fabrizia Vanzetta, Chiara Silacci, Blanca M. Fernandez-Rodriguez, Gloria Agatic, Siro Bianchi, Isabella Giacchetto-Sasselli, Lesley Calder, Federica Sallusto, Patrick Collins, Lesley F. Haire, Nigel Temperton, Johannes P. M. Langedijk, John J. Skehel, Antonio Lanzavecchia (2011). A Neutralizing Antibody Selected from Plasma Cells That Binds to Group 1 and Group 2 Influenza A Hemagglutinins: DOI:10.1126/science.1205669
• Cattoli G, Milani A, Temperton N, Zecchin B, Buratin A, Molesti E, Aly MM, Arafa A, Capua I (2011). Antigenic drift in H5N1 avian influenza in poultry is driven by mutations in major antigenic sites of the hemagglutinin molecule analogous to human influenza: Journal of Virology doi:10.1128/JVI.02403-10
• Hultberg A, Temperton NJ, Rosseels V, Koenders M, Gonzalez-Pajuelo M, Schepens B, Ibañez LI, Vanlandschoot P, Schillemans J, Saunders M, Weiss RA, Saelens X, Melero JA, Verrips CT, Van Gucht S, de Haard HJ (2011). Llama-derived single domain antibodies to build multivalent, superpotent and broadened neutralizing anti-viral molecules: PLoS One 6:e17665
• Ibañez LI, De Filette M, Hultberg A, Verrips T, Temperton N, Weiss RA, Vandevelde W, Schepens B, Vanlandschoot P, Saelens X (2011). Nanobodies with in vitro neutralizing activity protect mice against H5N1 influenza virus infection: Journal of Infectious Diseases 203, 1063-1072
• Loureiro S, Ren J, Phapugrangkul P, Colaco CA, Bailey CR, Shelton H, Molesti E, Temperton NJ, Barclay WS, Jones IM (2011). Adjuvant free immunisation with Hemagglutinin-Fc fusion proteins as an approach to influenza vaccines: Journal of Virology 85, 3010-3014
• Wright E, Hayman DT, Vaughan A, Temperton NJ, Wood JL, Cunningham AA, Suu-Ire R, Weiss RA, Fooks AR (2010). Virus neutralising activity of African fruit bat (Eidolon helvum) sera against emerging lyssaviruses: Virology 408, 183-189
• Corti D, Suguitan AL Jr, Pinna D, Silacci C, Fernandez-Rodriguez BM, Vanzetta F, Santos C, Luke CJ, Torres-Velez FJ, Temperton NJ, Weiss RA, Sallusto F, Subbarao K, Lanzavecchia A (2010). Heterosubtypic neutralizing antibodies are produced by individuals immunized with a seasonal influenza vaccine: Journal of Clinical Investigation 120, 1663-1673
• Temperton NJ (2010). The Use of Retroviral Pseudotypes for the Measurement of Antibody Responses to SARS Coronavirus. Chapter 17 in Lal,S.K. (ed.) Molecular Biology of the SARS-Coronavirus. Berlin: Springer-Verlag.
• Alberini I, Del Tordello E, Fasolo A, Temperton NJ, Galli G, Gentile C, Montomoli E, Hilbert AK, Banzhoff A, Del Giudice G, Donnelly JJ, Rappuoli R, Capecchi B (2009). Pseudoparticle neutralization is a reliable assay to measure immunity and cross-reactivity to H5N1 Influenza viruses: Vaccine 27, 5998-6003.
• Ascione A, Capecchi B, Campitelli L, Imperiale V, Flego M, Zamboni S, Gellini M, Alberini I, Pittiglio E, Donatelli I, Temperton NJ, Cianfriglia M (2009). Human monoclonal antibodies in single chain fragment variable format with potent neutralization activity against influenza virus H5N1: Antiviral Research 83, 238-244.
• Oh S, Selleck P, Temperton NJ, Chan PK, Manavis J, Higgins G, Burrell CJ, Kok T (2009). Neutralizing monoclonal antibodies to different clades of Influenza A H5N1 Viruses: Journal of Virological Methods 157, 161-167.
• Temperton NJ, Wright E (2009) Retroviral Pseudotypes. In: Encyclopedia of Life Sciences (ELS). John Wiley & Sons, Ltd: Chichester. DOI: 10.1002/9780470015902.a0021549.
• Li CK, Wu H, Yan H, Ma S, Wang L, Zhang M, Tang X, Temperton NJ, Weiss RA, Brenchley JM, Douek DC, Mongkolsapaya J, Tran BH, Lin SC, Screaton GR, Hou JL, McMichael AJ, Xu XN (2008). T Cell Responses to Whole SARS Coronavirus in Humans: Journal of Immunology 181, 5490-5500.
• Wright E, Temperton NJ, Marston DA, McElhinney LM, Fooks AR, Weiss RA (2008). Investigating antibody neutralization of lyssaviruses using lentiviral pseudotypes: a cross-species comparison: Journal of General Virology 89, 2204-2213.
• Su CY, Wang SY, Shie JJ, Jeng KS, Temperton NJ, Fang JM, Wong CH, Cheng YS (2008). In vitro evaluation of neuraminidase inhibitors using the neuraminidase-dependent release assay of hemagglutinin-pseudotyped viruses. Antiviral Research 79, 199-205.

Pre 2008

• Temperton NJ, Hoschler K, Major D, Nicolson C, Manvell R, Hien VM, Ha DQ, de Jong MD, Zambon M, Takeuchi Y, Weiss RA (2007). A Sensitive Retroviral Pseudotype Assay for Influenza H5N1 neutralizing antibodies: Influenza and other respiratory viruses 1, 105-112.
• Dye C, Temperton N, Siddell SG (2007). Type 1 feline coronavirus spike glycoprotein fails to recognize aminopeptidase N as a functional receptor on feline cell lines: Journal of General Virology 88, 1753-1760.
• Moyes D, Martin A, Sawcer S, Temperton N, Worthington J, Griffiths DJ, Venables PJ (2005). The distribution of the endogenous retroviruses HERV-K113 and –K115 in health and disease: Genomics 86, 336-341.
• Temperton NJ, Chan PK, Simmons G, Zambon MC, Tedder RS, Takeushi Y, Weiss RA (2005). Longitudinally profiling neutralizing antibody response to SARS Coronavirus with pseudotypes: Emerging Infectious Diseases 11, 411-416.
• Temperton NJ, Lawson KM, Quenelle DC, Zuckerman JN, Kern E, Griffiths PD, Emery VC (2003). Enhancement of humoral immune responses to a human cytomegalovirus DNA vaccine: adjuvant effects of aluminium phosphate and CpG ODN: Journal of Medical Virology 70, 86-90.